Introduction: , and are the causative agents of toxoplasmosis, trichomoniasis, and giardiasis, three important infections threatening human health and affecting millions of people worldwide. Although drugs and treatment are available to fight these protozoan parasites, side effects and increasing drug resistance require continuous efforts for the development of novel effective drugs.
Areas Covered: The patents search was carried out in September/October 2022 with four official scientific databases (Espacenet, Scifinder, Reaxys, Google Patents). Treatments for toxoplasmosis, trichomoniasis, and giardiasis (2015-2022) have been grouped according to their chemotypes. In particular, novel chemical entities have been reported and investigated for their structure-activity relationship, when accessible. On the other hand, drug repurposing, extensively exploited to obtain novel antiprotozoal treatment, has been in-depth described. Finally, natural metabolites and extracts have also been reported.
Expert Opinion: , and are protozoan infections usually controlled by immune system in immunocompetent patients; however, they could represent a threatening health for immunocompromised people. The needs of novel effective drugs, endowed with new mechanisms of actions, arises from the increasing drug resistance affecting antibiotic as well as antiprotozoal therapies. In this review different therapeutic approaches to treat protozoan infections have been reported.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/13543776.2023.2206017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Therapeutic potential of antimicrobial peptides against pathogenic protozoa.
Parasitol Res
February 2024
Faculdade de Farmácia and Centro de Biotecnologia, Universidade Federal Do Rio Grande Do Sul, Avenida Ipiranga, 2752, Porto Alegre, RS, CEP 90610-000, Brazil.
Protozoal infections cause significant morbidity and mortality in humans and animals. The use of several antiprotozoal drugs is associated with serious adverse effects and resistance development, and drugs that are more effective are urgently needed. Microorganisms, mammalian cells and fluids, insects, and reptiles are sources of antimicrobial peptides (AMPs) that act against pathogenic microorganisms; these AMPs have been widely studied as a promising alternative therapeutic option to conventional antibiotics, aiming to treat infections caused by multidrug-resistant pathogens.
View Article and Find Full Text PDFNovel therapeutic opportunities for , and infections.
Expert Opin Ther Pat
March 2023
Department of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, Italy.
Introduction: , and are the causative agents of toxoplasmosis, trichomoniasis, and giardiasis, three important infections threatening human health and affecting millions of people worldwide. Although drugs and treatment are available to fight these protozoan parasites, side effects and increasing drug resistance require continuous efforts for the development of novel effective drugs.
Areas Covered: The patents search was carried out in September/October 2022 with four official scientific databases (Espacenet, Scifinder, Reaxys, Google Patents).
Is There Any Relationship between Infection and Male Urethritis Risk? A Systematic Review and Meta-Analysis.
Interdiscip Perspect Infect Dis
September 2022
Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
Background: Male urethritis is one of the most common genital tract syndromes. Though the number of patients with urethritis is increasing worldwide, the cause of many cases of non-gonococcal urethritis (NGU) is still unknown.
Objectives: This study aimed to delineate the association between () infection and male urethritis.
Green synthesis of nano-liposomes containing Bunium persicum and Trachyspermum ammi essential oils against Trichomonasvaginalis.
J Microbiol Immunol Infect
February 2023
Department of Biological Chemistry, Regional University of Cariri - URCA, Crato, Brazil. Electronic address:
Background: Trichomonas vaginalis, a parasitic flagellated protozoan, is one of the main non-viral sexually transmitted diseases worldwide. Treatment options for trichomoniasis are limited to nitroimidazole compounds. However, resistance to these drugs has been reported, which requires the development of new anti-Trichomonas agents that confer suitable efficacy and less toxicity.
View Article and Find Full Text PDFPromising potent in vitro activity of curcumin and quercetin nano-niosomes against Trichomonas vaginalis.
Ann Parasitol
July 2022
Department of Pharmaceutics, Faculty of Pharmacy, Alborz University of Medical Sciences, Karaj, Iran.
Trichomonosis, caused by infection with a motile protozoan parasite called Trichomonas vaginalis, is the most common non-viral sexually transmitted disease worldwide. Since the 1960s, metronidazole has been used as a drug of choice. Considering increased resistance to anti-trichomonial drugs, alternative treatments are urgently needed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!